Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan den Broeder

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Annals of the Rheumatic Diseases|December 21, 2025
Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumaticaThomas E Bolhuis, Noortje E S E P Kooijman, Diane E Marsman, et al.
Clinical Pharmacology and Therapeutics|July 10, 2023
Non-Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational StudyNathan den Broeder, Alfons A den Broeder, Lise M Verhoef, et al.
Annals of the Rheumatic Diseases|April 23, 2020
Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARDEvy Ulijn, Nathan den Broeder, Maike Wientjes, et al.
Annals of the Rheumatic Diseases|June 14, 2022
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trialCelia Aj Michielsens, Nathan den Broeder, Frank Hj van den Hoogen, et al.
Digestive Diseases and Sciences|May 2, 2023
Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine TherapyFenna M Jansen, Lisa J T Smits, Pepijn W A Thomas, et al.
Inflammatory Bowel Diseases|February 8, 2022
Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective StudyPepijn W A Thomas, Nathan den Broeder, Monique Derikx, et al.
Rheumatology (Oxford, England)|January 13, 2022
Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximabMaike H M Wientjes, Titia M G Gijzen, Nathan den Broeder, et al.
Trials|February 12, 2020
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)Michelle L M Mulder, Johanna E Vriezekolk, Nathan den Broeder, et al.
Trials|September 1, 2017
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trialAlfons A den Broeder, Lise M Verhoef, Jaap Fransen, et al.
Clinical and Experimental Rheumatology|October 10, 2018
Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritisElien A M Mahler, Alfons A den Broeder, Nathan den Broeder, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Annals of the Rheumatic Diseases|December 21, 2025
Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumaticaThomas E Bolhuis, Noortje E S E P Kooijman, Diane E Marsman, et al.
Clinical Pharmacology and Therapeutics|July 10, 2023
Non-Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational StudyNathan den Broeder, Alfons A den Broeder, Lise M Verhoef, et al.
Annals of the Rheumatic Diseases|April 23, 2020
Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARDEvy Ulijn, Nathan den Broeder, Maike Wientjes, et al.
Annals of the Rheumatic Diseases|June 14, 2022
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trialCelia Aj Michielsens, Nathan den Broeder, Frank Hj van den Hoogen, et al.
Digestive Diseases and Sciences|May 2, 2023
Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine TherapyFenna M Jansen, Lisa J T Smits, Pepijn W A Thomas, et al.
Inflammatory Bowel Diseases|February 8, 2022
Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective StudyPepijn W A Thomas, Nathan den Broeder, Monique Derikx, et al.
Rheumatology (Oxford, England)|January 13, 2022
Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximabMaike H M Wientjes, Titia M G Gijzen, Nathan den Broeder, et al.
Trials|February 12, 2020
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)Michelle L M Mulder, Johanna E Vriezekolk, Nathan den Broeder, et al.
Trials|September 1, 2017
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trialAlfons A den Broeder, Lise M Verhoef, Jaap Fransen, et al.
Clinical and Experimental Rheumatology|October 10, 2018
Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritisElien A M Mahler, Alfons A den Broeder, Nathan den Broeder, et al.
Pageof 6